Regado Rises on REG1 Fast Track Designation - Analyst Blog


Shutterstock photo

Shares of Regado Biosciences, Inc. ( RGDO ) soared 38.1% and also touched a 52-week high after the U.S. Food and Drug Administration (FDA) granted a fast track designation to the company's lead candidate, REG1 (consisting of pegnivacogin and anivamersen). The candidate is being developed as an anticoagulant for patients suffering from coronary artery disease during percutaneous coronary interventions (PCI).

We note that the FDA grants fast track designation to those candidates that are being developed for the treatment of serious conditions with unmet medical need, with the overall goal of getting new drugs to patients faster.

Regado is currently enrolling patients in the phase III REGULATE-PCI study on REG1 in those suffering from coronary artery disease undergoing PCI. Regado intends to complete enrollment of the first 1000 patients for this study in the second quarter of 2014. If the phase III study succeeds, Regado will be filing regulatory applications in early 2016.

We are encouraged by the U.S. regulatory authority granting fast track designation to REG1. We expect investor focus to remain on REG1 going forward. Meanwhile, Regado also has REG2 in its pipeline. Last month, the FDA accepted the company's investigational new drug application for REG2.

Regado is evaluating REG2 in a wide range of acute and sub-acute care cardiovascular indications such as venous thromboembolism prophylaxis in patients undergoing abdominal surgery. Regado is also evaluating REG2 for treating transcatheter aortic valve implantation patients and for bridging patients who are unable to take oral anticoagulants. The company also intends to conduct further clinical testing in sub-acute venous thrombosis indications.

Regado currently carries a Zacks Rank #2 (Buy). Right now, investors may also consider Alexion Pharmaceuticals, Inc. ( ALXN ), Alkermes ( ALKS ) and Actelion Ltd. ( ALIOF ). While Alexion and Alkermes hold a Zacks Rank #1 (Strong Buy), Actelion carries a Zacks Rank #2.


ALKERMES INC (ALKS): Free Stock Analysis Report

ALEXION PHARMA (ALXN): Free Stock Analysis Report

REGADO BIOSCI (RGDO): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: Investing , Business , Stocks
More Headlines for: PCI , ALIOF , ALKS , ALXN , RGDO

More from


Equity Research
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by